1-[5-(3-Acetylphenyl)-1-methylpyrazol-3-yl]-3-[2-(3-methylbutoxy)phenyl]urea | 1253411-17-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[5-(3-Acetylphenyl)-1-methylpyrazol-3-yl]-3-[2-(3-methylbutoxy)phenyl]urea
• CAS: 1253411-17-4
• 化学式: C₂₄H₂₈N₄O₃
• 分子量: 420.511
• InChiKey: VOATZCXPOPXWLZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  85.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-溴代异戊烷 在 palladium on activated carbon 氢气 、 potassium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 N-甲基吡咯烷酮 、 甲醇 为溶剂， 反应 3.0h， 生成 1-[5-(3-Acetylphenyl)-1-methylpyrazol-3-yl]-3-[2-(3-methylbutoxy)phenyl]urea
  参考文献：
  名称：

  EP2426135

  摘要：

  公开号：

文献信息

• UREA DERIVATIVE HAVING PI3K INHIBITORY ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：EP2426135A1

  公开（公告）日：2012-03-07

  Provided is a compound or a pharmaceutically acceptable salt thereof which inhibits the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and is therefore useful for the prophylaxis/therapy of diseases including inflammatory diseases, arteriosclerosis, vascular/circulatory diseases, cancer/tumors, immune system diseases, cell proliferative diseases, infectious diseases, and the like. The above problem was solved by providing a urea derivative shown in the present specification, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种化合物或其药学上可接受的盐，可抑制 PI3K 的活性，从而调节许多生物过程，包括细胞的生长、分化、存活、增殖、迁移、新陈代谢等，因此可用于疾病的预防/治疗，包括炎症性疾病、动脉硬化、血管/循环系统疾病、癌症/肿瘤、免疫系统疾病、细胞增殖性疾病、传染性疾病等。通过提供本说明书所示的脲衍生物或其药学上可接受的盐，上述问题得以解决。
• UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY
  申请人：Taniyama Daisuke

  公开号：US20120071475A1

  公开（公告）日：2012-03-22

  Provided is a compound or a pharmaceutically acceptable salt thereof which inhibits the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and is therefore useful for the prophylaxis/therapy of diseases including inflammatory diseases, arteriosclerosis, vascular/circulatory diseases, cancer/tumors, immune system diseases, cell proliferative diseases, infectious diseases, and the like. The above problem was solved by providing a urea derivative shown in the present specification, or a pharmaceutically acceptable salt thereof.
• EP2426135
  申请人：——

  公开号：——

  公开（公告）日：——